The Safety of the 6-minute Walk Test After Acute Myocardial Infarction
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Solange Guizilini, PhD
- Phone Number: 5511982887753
- Email: s_guizilini@yahoo.com.br
Study Contact Backup
- Name: Graciana Santos Martinhão
- Phone Number: 5511999297715
- Email: graciana_martinhao@hotmail.com
Study Locations
-
-
-
São Paulo, Brazil, 04024002
- Recruiting
- Graciana Santos Martinhão
-
Contact:
- Investigator
- Phone Number: 5511999297715
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- AMI patients
Exclusion Criteria:
- Previous history of AMI
- Recurrent or refractory pain
- Presence of neuromuscular diseases
- Acute or chronic lung diseases
- Inability to perform the functional test
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
In-hospital acute myocardial infarction patients
Functional Capacity Assessment
|
Individuals will be assessed on the third day after acute myocardial infarction.
The six-minute walk test will be performed according to the norms of the American Thoracic Society.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six-minute walk test to measure functional capacity
Time Frame: Third day after acute myocardial infarction
|
By 6MWT assessing the functional capacity after acute myocardial infarction
|
Third day after acute myocardial infarction
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Angina
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of angina during the 6MWT
|
Third day after acute myocardial infarction
|
|
Dyspnea
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of dyspnea during the 6MWT
|
Third day after acute myocardial infarction
|
|
Pallor
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of pallor during the 6MWT
|
Third day after acute myocardial infarction
|
|
Sweating
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of sweating during the 6MWT
|
Third day after acute myocardial infarction
|
|
Cramps
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of cramps during the 6MWT
|
Third day after acute myocardial infarction
|
|
Lower limbs fatigue
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of lower limbs fatigue during the 6MWT
|
Third day after acute myocardial infarction
|
|
Dizziness
Time Frame: Third day after acute myocardial infarction
|
To assess the occurrence of dizziness during the 6MWT
|
Third day after acute myocardial infarction
|
|
Hospitalization stay
Time Frame: Thirty days after acute myocardial infarction
|
Duration of stay in the hospital (in days) will be recorded.
|
Thirty days after acute myocardial infarction
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 58277816.7.0000.5505
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.